2023 Guidance and Q3 Earnings

A focused global biopharma company with clear momentum that is delivering GSK Strategy focused on prevention and treatment to get ahead of disease together World leader in infectious disease with a broader pipeline based on science of the immune system Highly attractive medium-term¹ target for sales and adjusted operating profit CAGR² Innovation progress underscores confidence in ability to sustain profitable growth through the decade and beyond GSK 1. Medium-term is 2021-2026, excluding COVID-19 solutions 2. Compound annual growth rate at constant exchange rates (CER) 27 22

View entire presentation